Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?
Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA. Franceschi E, et al. Among authors: pession a. Future Oncol. 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25. Future Oncol. 2018. PMID: 29938525
Patient outcomes following second surgery for recurrent glioblastoma.
Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C, Pession A, Bortolotti C, Zucchelli M, Galzio R, Talacchi A, Volpin L, Marucci G, de Biase D, Pizzolitto S, Danieli D, Ermani M, Franceschi E. Brandes AA, et al. Among authors: pession a. Future Oncol. 2016;12(8):1039-44. doi: 10.2217/fon.16.9. Epub 2016 Feb 16. Future Oncol. 2016. PMID: 26880307
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.
Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Brandes AA, et al. Among authors: pession a. Oncologist. 2017 Apr;22(4):432-437. doi: 10.1634/theoncologist.2016-0254. Epub 2017 Mar 8. Oncologist. 2017. PMID: 28275120 Free PMC article.
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G, Brandes AA, de Biase D. Visani M, et al. Among authors: pession a. J Neurooncol. 2017 Nov;135(2):245-254. doi: 10.1007/s11060-017-2571-0. Epub 2017 Jul 26. J Neurooncol. 2017. PMID: 28748342
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, Pession A, De Biase D, Minichillo S, Tosoni A, Di Battista M, Cubeddu A, Bartolini S, Brandes AA. Franceschi E, et al. Among authors: pession a. Future Oncol. 2018 May;14(11):1063-1069. doi: 10.2217/fon-2017-0681. Epub 2018 May 9. Future Oncol. 2018. PMID: 29741106
Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.
de Biase D, Acquaviva G, Visani M, Marucci G, De Leo A, Maloberti T, Sanza V, Di Oto E, Franceschi E, Mura A, Ragazzi M, Serra S, Froio E, Bisagni A, Brandes AA, Pession A, Tallini G. de Biase D, et al. Among authors: pession a. J Mol Diagn. 2021 Sep;23(9):1185-1194. doi: 10.1016/j.jmoldx.2021.06.004. Epub 2021 Jun 26. J Mol Diagn. 2021. PMID: 34186176 Free article.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. Among authors: pession a. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. de Biase D, et al. Among authors: pession a. PLoS One. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PLoS One. 2017. PMID: 28520821 Free PMC article.
692 results